|
|

Title: Melanins with improved ability to inhibit HIV
replication
United States Patent: 6,300,057
Inventors: Garger, Jr.; Steven (Vacaville, CA); Neidleman;
Saul (Oakland, CA)
Assignee: Large Scale Biology Corporation (Vacaville, CA)
Appl. No.: 796822
Filed: February 6, 1997
Abstract
Novel enzymatically produced melanins are described that are useful in
the treatment of HIV infection. The novel remanins are optionally modified
to contain chemical moieties such as halogens, sulfates, or sulfonyl
groups. Additionally, the novel enzymatically synthesized melanins may be
modified, or further modified, by chemical oxidation.
SUMMARY OF THE INVENTION
To achieve this end, a first aspect of the present invention relates to a
novel method for arresting HIV replication as a therapy for persons
exposed to the HIV virus or testing HIV-positive, and for AIDS patients by
administering an effective dose of melanin derived from the controlled
enzymatic action of tyrosinase in conjunction with specific substrates or
mixtures of substrates.
A second aspect of the invention relates to methods for the chemical
polysulfation of enzymatically or non-enzymatically produced melanin to
increase antiviral activity, as well as the sulfated or polysulfated
melanin products of such methods.
A third aspect of the invention relates to methods for the chemical
polyhalogenation of melanin with fluorine, chlorine, bromine and/or iodine
to increase antiviral activity, as well as the halogenated melanin
products of such methods.
A fourth aspect of the invention relates to the therapeutic use of
melanins that have been modified by any combination of polysulfation,
polysulfonation, and/or polyhalogenation.
A fifth aspect of the invention relates to melanins produced by enzymatic
synthesis using defined substrates, and modified forms thereof, that have
been purified by precipitation by reducing the pH of a melanin containing
solution below about 7.0, and preferably below about pH 3.0, with a
preferred pH of about 1.5.
A sixth aspect of the invention relates to melanin produced by enzymatic
synthesis wherein said melanin is oxidized by hydrogen peroxide or another
suitable chemical oxidizer.
A seventh aspect of the invention relates to melanin produced by enzymatic
synthesis wherein said melanin is further purified by passage through a
suitable molecular sieve to obtain melanin having a molecular size greater
than or equal to about 10,000 daltons.
An eighth aspect of the invention relates to melanin produced by either
chemical or enzymatic synthesis wherein said melanin is further modified
to have chemical subgroups selected from the group consisting of sulfonyl,
sulfate and halogen chemical groups, or any mixture thereof.
Claim 1 of 30 Claims
What is claimed is:
1. A method for treating HIV infection, comprising administrating a
therapeutically effective dose of melanin wherein said melanin is
synthesized by chemical or enzymatic methods and contains at least one
anionic group selected from the group consisting of sulfates and sulfonyls.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|